Brian Patrick Tullius, MD

Brian Patrick Tullius , MD

Physician

Cancer

Dr. Tullius

Overview

Brian Tullius, MD, is a board-certified pediatrician. Dr. Tullius received his medical degree at the University of Nebraska College of Medicine in Omaha Nebraska after completing a Master of Arts degree in Philosophy and a Bachelor of Arts in Philosophy and Biology from Franciscan University of Steubenville in Steubenville, Ohio. He has extensive training in pediatrics, completing pediatric internship at the Naval Medical Center in San Diego and pediatric residency at the University of California-Davis Medical Center in Sacramento. Dr. Tullius completed flight surgeon training at the Naval Aerospace Medical Institute in Pensacola, FL, and his pediatric hematology/oncology as well as his cellular therapy fellowships at Nationwide Children’s Hospital in Columbus, Ohio. He served in the United States Navy achieving the rank of Lieutenant Commander and receiving numerous awards and commendations for his outstanding service. Dr. Tullius has a U.S. Patent on a cellular therapy for treating microbial infections, and a patent pending for an innovative website he helped design to improve access to and awareness of clinical trials. An accomplished medical practitioner, Dr. Tullius specializes in cellular therapies, cancer immunotherapy, innate immunity and stem cell transplantation.

Articles

Knockout of the inhibitory receptor TIGIT enhances the antitumor response of ex vivo expanded NK cells and prevents fratricide with therapeutic Fc-active TIGIT antibodies

JOURNAL FOR IMMUNOTHERAPY OF CANCER

2023

CRISPR Gene Editing of Human Primary NK and T Cells for Cancer Immunotherapy

FRONTIERS IN ONCOLOGY

2022

Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future

STEM CELL RESEARCH & THERAPY

2021

COVID-19 in immunocompromised patients: A systematic review of cancer, hematopoietic cell and solid organ transplant patients

JOURNAL OF INFECTION

2021

Genetic and epigenetic modification of human primary NK cells for enhanced antitumor activity

SEMINARS IN HEMATOLOGY

2020

Natural Killer Cell Immunotherapy for Osteosarcoma

CURRENT ADVANCES IN OSTEOSARCOMA: CLINICAL PERSPECTIVES: PAST, PRESENT AND FUTURE, 2ND EDITION

2020

Therapeutic modulation of the CD47-SIRPalpha axis in the pediatric tumor microenvironment: working up an appetite.

Cancer drug resistance (Alhambra, Calif.)

2020

Novel heterozygous mutation in the PTEN gene associated with ovarian germ cell tumor complicated by growing teratoma syndrome and overgrowth in a two-year-old female

PEDIATRIC BLOOD & CANCER

2019

Hospital-to-Home Interventions, Use, and Satisfaction: A Meta-analysis

PEDIATRICS

2018

The identification of at-risk patients and prevention of venous thromboembolism in pediatric cancer: guidance from the SSC of the ISTH

JOURNAL OF THROMBOSIS AND HAEMOSTASIS

2018

More Publication Information

Education & Training

Education

University of Nebraska College of Medicine, Omaha, NE

Residency

Pediatrics at UC Davis School of Medicine

Fellowship

Bone Marrow at Nationwide Children's Hospital

Associated Clinical Trials

NCT04836390

A Phase II Pilot Study of Donor-Derived Ex-VivoExpanded Natural Killer Cell Infusions in Childrenand Young Adults with High-Risk Acute Myeloid Leukemia Receiving Myeloablative HLA Haploidentical Hematopoietic Cell Transplant: A Multicenter Pediatric Transplantation and Cellular Therapy Consortium (PTCTC) Study (EXCEL Trial) PTCTC CT2001.

Icon for trial | CT2001 A Phase II Pilot Study of Donor-Derived Ex-VivoExpanded Natural Killer Cell Infusions in Childrenand Young Adults with High-Risk Acute Myeloid Leukemia Receiving Myeloablative HLA Haploidentical Hematopoietic Cell Transplant: A Multicenter Pediatri

This study is currently enrolling.

Participants will be invited to join this study if they have a blood disease called acute myeloid leukemia (AML) and it has been decided that they need a transplant as part of their treatment plan. The purpose of this research ...